The hefty funding will fuel Phase 2 testing of a drug with a similar mechanism to Amgen’s closely watched obesity drug, as ...

Backed by more than a dozen prominent investors, the startup is advancing into human testing a drug it believes capable of ...

The startup is developing a medicine that can very specifically degrade cancerous forms of EGFR, the target of an array of ...

The financing, which will back a novel type of cancer drug, is the largest of a series of startup fundings announced at the ...

The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an ...

Arrowhead’s RNA drugs could aid with “high-quality” weight loss, according to one analyst. Elsewhere, the PD-1/VEGF field got ...

By the end of March, the agency could approve multiple “national priority” voucher winners, as well as a gene therapy it ...

After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease ...

Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...

AI is no longer a distant concept; it is reshaping industries today. For pharmaceutical companies, the question is clear: how ...

The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that ...

In a drastic decision made outside of its typical review process, the agency declared it would recommend 11 childhood shots ...